Crossject reported a 0.6% rise in its share count between August and October, while its latest filing also detailed the French drugmaker’s theoretical and exercisable voting rights.
In the filing published Nov. 6, Crossject said it had 60,710,815 shares on Oct. 31. That was 357,648 more than the 60,353,167 shares reported at Aug. 31, a rise of about 0.6% based on the company’s figures.
The company listed 72,412,767 theoretical voting rights and 72,367,119 exercisable voting rights. It said 45,648 shares carried no voting rights: 31,689 treasury shares and 13,959 recorded under its liquidity contract. The exercisable total was 45,648 below the theoretical tally.
Crossject says it develops emergency-use products using its ZENEO needle-free autoinjector. It made the disclosure under Article 223-16 of the General Regulation of the Autorité des marchés financiers (AMF) and Article L.233-8 II of the French Commercial Code.
